BeiGene (BGNE)
(Delayed Data from NSDQ)
$162.25 USD
+0.24 (0.15%)
Updated May 3, 2024 04:00 PM ET
After-Market: $161.91 -0.34 (-0.21%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BGNE 162.25 +0.24(0.15%)
Will BGNE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BGNE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BGNE
BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?
3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024
BGNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Top 5 Momentum Picks for January After a Fabulous 2023
New Strong Buy Stocks for December 22nd
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
Other News for BGNE
BeiGene, AbbVie patent spat to get trial from USPTO appeals board
Tracking Last Week's Top Performers: Are These 15 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)
Tracking Last Week's Top Performers: Are These 15 Large-Cap Stocks In Your Portfolio? (April 21-27)
AstraZeneca: Strong In A Weak Market
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report